The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
MPN Workshop of the Carolinas 2025 | Assessing the symptom burden of patients with MPNs in the clinic
Ruben Mesa, MD, Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston Salem, NC, outlines the validated tools available for assessing symptom burden in patients with myeloproliferative neoplasms (MPNs), which are publicly available and can be used in both paper and electronic formats. Dr Mesa emphasizes the importance of evaluating relative changes in symptom burden for individual patients, rather than comparing absolute scores between patients, and considering the granularity of scores to understand the impact of symptoms as a whole. This interview took place at the 2nd Annual MPN Workshop of the Carolinas, held in Charlotte, NC.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So now we have highly validated tools for measuring symptoms in MPN patients. Both the MPN symptom assessment form, which is the longest form, the MPN 10, which is kind of a 10 core item, or we have a smaller form for myelofibrosis. One, these forms are both overlapping, but they’re publicly available. They can be used in paper. There are many electronic versions...
So now we have highly validated tools for measuring symptoms in MPN patients. Both the MPN symptom assessment form, which is the longest form, the MPN 10, which is kind of a 10 core item, or we have a smaller form for myelofibrosis. One, these forms are both overlapping, but they’re publicly available. They can be used in paper. There are many electronic versions. And again, the key to remember with these forms is that one, the patient is their own control, so the form is not to compare the absolute score between two patients but to really see the relative change for that one individual. I also really look and I ask the patients, “Well, which of the symptoms are the most problematic?” both by score, but not the total score matters, but also really the granularity of a score. If you have a patient that has two items which are a 10 out of 10, that patient may be more impacted than an individual that has 10 items that each are a 2. So a lot of low-grade symptoms may not necessarily be as impactful as one or two that are highly symptomatic.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
